Four novel fluorescence active ligands (1‐4) consisting of a 1H‐tetrazol‐1‐yl moiety as coordinating unit and a 4,4‐difluoro‐4‐bora‐3a,4a‐diaza‐s‐indacene (BODIPY) derivative as fluorophore, bridged via alkyl (‐(CH2)n‐, n = 1‑3) or benzyl (‐CH2‐C6H4‐) spacers were designed. Successful synthesis is demonstrated by multinuclear NMR spectroscopy, as well as powder and single crystal XRD analysis. The methylene bridged ligand 2 (4,4‐difluoro‐1,3,5,7‐tetramethyl‐8‐[(1H‐tetrazol‐1‐yl)methyl]‐4‐bora‐3a,4a‐diaza‐s‐indacene) crystallizes in different polymorphs and solvatomorphs, in contrast to the other three ligands, which show no polymorphism under identical conditions. Photophysical studies revealed high fluorescence quantum yields (69 – 95%) in solution for the ‐(CH2)2‐ bridged ligand 3 (4,4‐difluoro‐1,3,5,7‐tetramethyl‐8‐[(1H‐tetrazol‐1‐yl)ethyl]‐4‐bora‐3a,4a‐diaza‐s‐indacene) and the ‐(CH2)3‐ bridged ligand 4 (4,4‐difluoro‐1,3,5,7‐tetramethyl‐8‐[(1H‐tetrazol‐1‐yl)propyl]‐4‐bora‐3a,4a‐diaza‐s‐indacene). Non‐radiative decay due to rotational motion of the 1H‐tetrazol‐1‐yl‐ and/or ‐CH2‐C6H4‐ moiety for 2 and 1 (4,4‐difluoro‐1,3,5,7‐tetramethyl‐8‐[4‐((1H‐tetrazol‐1‐yl)methyl)phenyl]‐4‐bora‐3a,4a‐diaza‐s‐indacene) respectively leads to reduced quantum yields of ≥ 35%. Complete fluorescence quenching upon aggregation is prevented by installation of the sterically demanding 1H‐tetrazol‐1‐yl moiety and a spacer in meso‐position of the BODIPY core to elongate the intermolecular distances between two adjacent BODIPY cores. Detailed photophysical and crystallographic investigations are supported by theoretical calculations.
Read full abstract